These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15297854)

  • 21. [Thalidomide with or without dexamethasone for refractory multiple myeloma].
    Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ
    Therapie; 2002; 57(6):524-9. PubMed ID: 12666259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma cell leukemia: concepts and management.
    Liedtke M; Medeiros BC
    Expert Rev Hematol; 2010 Oct; 3(5):543-9. PubMed ID: 21083471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance therapy for multiple myeloma with particular emphasis on thalidomide.
    Dürk HA
    Onkologie; 2006 Dec; 29(12):582-90. PubMed ID: 17202830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
    Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; de Vivo A; Palareti G; Tura S; Baccarani M
    Haematologica; 2004 Jul; 89(7):826-31. PubMed ID: 15257934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
    Pretz J; Medeiros BC
    Am J Hematol; 2009 Oct; 84(10):698-9. PubMed ID: 19691102
    [No Abstract]   [Full Text] [Related]  

  • 26. Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report.
    Vo K; Guan T; Banerjee R; Lo M; Young R; Shah N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1244-1248. PubMed ID: 35084252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of thalidomide in multiple myeloma.
    Schwab C; Jagannath S
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):26-9. PubMed ID: 16879766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
    Hosono N; Yamauchi T; Nakamura T; Yamashita T; Ueda T
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):533-7. PubMed ID: 18347412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolving role of novel agents for maintenance therapy in myeloma.
    Magarotto V; Palumbo A
    Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
    Yakoub-Agha I; Attal M; Dumontet C; Delannoy V; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux V; Bay JO; Monconduit M; Harousseau JL; Duguet C; Duhamel A; Facon T
    Hematol J; 2002; 3(4):185-92. PubMed ID: 12189564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of multiple myeloma: an emphasis on new developments.
    Kyle RA; Vincent Rajkumar S
    Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thalidomide-associated hepatitis: a case report.
    Fowler R; Imrie K
    Am J Hematol; 2001 Apr; 66(4):300-2. PubMed ID: 11279644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone.
    Ramasamy K; Lim Z; Pagliuca A; Salisbury JR; Mufti GJ; Devereux S
    Haematologica; 2006 Aug; 91(8 Suppl):ECR44. PubMed ID: 16923528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
    Musto P; Simeon V; Martorelli MC; Petrucci MT; Cascavilla N; Di Raimondo F; Caravita T; Morabito F; Offidani M; Olivieri A; Benevolo G; Mina R; Guariglia R; D'Arena G; Mansueto G; Filardi N; Nobile F; Levi A; Falcone A; Cavalli M; Pietrantuono G; Villani O; Bringhen S; Omedè P; Lerose R; Agnelli L; Todoerti K; Neri A; Boccadoro M; Palumbo A
    Leukemia; 2014 Jan; 28(1):222-5. PubMed ID: 23958922
    [No Abstract]   [Full Text] [Related]  

  • 36. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia.
    Johnston RE; Abdalla SH
    Leuk Lymphoma; 2002 Feb; 43(2):351-4. PubMed ID: 11999568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
    Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
    Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia.
    Barton JC
    Am J Hematol; 2003 Nov; 74(3):205-7. PubMed ID: 14587053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.